Avoid injecting directly into the tendon itself, as this can cause additional trauma
BPC-157 may be better for musculoskeletal and inflammatory issues, while TB500 might be preferred for broader tissue repair due to its actin regulation
In each of these conditions, DPD acts as a biomarker of disease activity
While these are population-level numbers, the principle applies to individuals as well: routine injection visits for non-deficient patients add up in copays, travel time, and appointment scheduling without delivering additional benefit
Translating animal dosing to human equivalents introduces risk without clinical guidance
The standard combination protocol uses BPC-157 at 0.25-0.5 mg daily alongside TB-500 at 2-5 mg weekly during a loading phase of 4 weeks, followed by TB-500 maintenance at 2-3 mg weekly while continuing daily BPC-157